Are AstraZeneca plc, Indivior PLC & Dechra Pharmaceuticals plc Set To Double by 2016?

AstraZeneca plc (LON:AZN), Indivior PLC (LON:INDV) and Dechra Pharmaceuticals plc (LON:DPH) offer three very different risk profiles, argues Alessandro Pasetti.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If you are looking for relatively stable cash flows and solid balance sheets in a volatile market, there is a good chance that you may be right to invest in the pharmaceuticals sector right now. 

That works in theory, at least — but is there also a change that the shares of AstraZeneca (LSE: AZN), Indivior (LSE: INDV) and Dechra (LSE: DPH) will double in value by the end of 2016? 

Could Astra double in value? 

Astra is a nice yield play but is very unlikely, however, to deliver meaningful capital gains into 2016 and beyond, in my view. Its stock is currently at about 4,200p, but I wouldn’t be surprised if it traded some 500p lower by the end of the year. A drop in its valuation could be an opportunity perhaps, but then would I bet on a stock price of 7,000p?

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Astra is on track to deliver earnings per share (EPS) of $2 this year, which puts its stock on a price-to-earnings (P/E) multiple of 30 times for 2015. Assuming that it can then grow EPS by 50% to $3 in 2016, a price target of 7,000p would imply a 2016 forward P/E multiple of 35 times. Ouch! 

The problem is that the market has pencilled only a 10% rise in EPS in 2016 — and that’s a generous assumption. On this basis, at its current price I’d be now paying 27 times for its 2016 forward earnings (and 45 times assuming a price target of 7,000p), which is a crazy valuation for a mature business offering flat revenues and margins. 

Indivior: Lots to like in it!

The stock of Indivior, a market leader in the treatment of opioid dependence, has become more expensive since it was spun off from Reckitt, but its shares are not that expensive, really — although it has a problem with generic competitors. Moreover, its size renders it an appealing takeover target, but an M&A premium is not priced into its shares, I’d argue. I’d expect lower earnings in future than in the past, but how much would INDV cost me based on its earnings profile? 

In the first half of the year, EPS was 20 cents (H1 2014: 32 cents) both on a basic and fully diluted basis. Full-year guidance was raised earlier this summer when the company said that it expected net revenue in the range of $935m to $965m and net income of $185m to $210m at constant exchange rates.

So, if it hits the top end of its estimates, Indivior will report EPS of 28 cents on a fully diluted basis, based on about 733m shares outstanding.

Its stock price now is 224p. Once it’s converted into US dollars at the prevailing $/£ exchange rate, its implied 2015 forward P/E multiple comes in at 11.7 times. Well, I’d rather bet on a rise in its P/E to over 20 times in 2016, hoping that investors will be willing to pay that much for Indivior stock — even it generates a marginally lower level of earnings next year — than 27 times for Astra’s forward earnings, to be honest!

Dechra Pharmaceuticals: it’s pricey!

Dechra is a more complicated investment case. Even at a glance this is really a good business, and its results this week confirmed that view. 

Its excellent performance showed all the way through its income statements, but here we are looking to double the value of our investment, and its prospects — its shares trade in Astra’s ballpark, based on P/E multiples — are less appealing than those of Indivior. For that reason, as well as considering its level of underlying profitability, which is 15 percentage points below Indivior’s (as gauged by their operating income margins), I’d not be prepared to bet on a steep rise in its equity valuation, although a takeover premium doesn’t seem to be priced into its shares. 

However, don’t buy any shares just yet

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Secure your FREE copy

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 in savings? Here’s how it could be used to target a £913 second income each month

Christopher Ruane walks through some practicalities of how an idle £20k could be the foundation for a sizeable long-term second…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

5 steps to building monthly passive income with a spare £10k

Christopher explains how an investor could aim to use some spare cash to start building regular passive income streams through…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

Tesla’s struggling. Could NIO stock benefit?

NIO stock has moved up very slightly this year, while Tesla has crashed. Our writer considers whether it might be…

Read more »

Two employees sat at desk welcoming customer to a Tesla car showroom
Investing Articles

Could Tesla stock be a brilliant bargain in plain sight?

Christopher Ruane sees some things to like about Tesla, but as its vehicle revenues have gone into sharp decline, is…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

3 cheap FTSE 250 stocks with big dividends to consider buying right now

The FTSE 250's loaded with so many big dividend yields it's hard to know where to start. These three have…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up 585%, could Rolls-Royce shares still go higher?

Christopher Ruane likes the Rolls-Royce business but is not so convinced by the value its current share price offers him.…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

I reckon a bull market’s coming! Here’s what I’m buying for my Stocks and Shares ISA

Hoping to capitalise on what he believes is an undervalued UK stock market, our writer’s added more of this FTSE…

Read more »

piggy bank, searching with binoculars
Investing Articles

The UK stock market looks undervalued to me. Here’s 1 growth stock to consider for a SIPP

Our writer explains why he thinks the UK stock market’s currently in bargain territory, and identifies one share potentially worthy…

Read more »